Your browser doesn't support javascript.
loading
Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies.
Shankar-Hari, Manu; Calandra, Thierry; Soares, Miguel P; Bauer, Michael; Wiersinga, W Joost; Prescott, Hallie C; Knight, Julian C; Baillie, Kenneth J; Bos, Lieuwe D J; Derde, Lennie P G; Finfer, Simon; Hotchkiss, Richard S; Marshall, John; Openshaw, Peter J M; Seymour, Christopher W; Venet, Fabienne; Vincent, Jean-Louis; Le Tourneau, Christophe; Maitland-van der Zee, Anke H; McInnes, Iain B; van der Poll, Tom.
Afiliación
  • Shankar-Hari M; Institute for Regeneration and Repair, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, UK. Electronic address: manu.shankar-hari@ed.ac.uk.
  • Calandra T; Service of Immunology and Allergy, Center of Human Immunology Lausanne, Department of Medicine and Department of Laboratory Medicine and Pathology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
  • Soares MP; Instituto Gulbenkian de Ciência, Oeiras, Portugal.
  • Bauer M; Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.
  • Wiersinga WJ; Center for Experimental and Molecular Medicine and Division of Infectious Diseases, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
  • Prescott HC; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Knight JC; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Baillie KJ; Institute for Regeneration and Repair, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, UK.
  • Bos LDJ; Department of Intensive Care, Academic Medical Center, Amsterdam, Netherlands.
  • Derde LPG; Intensive Care Center, University Medical Center Utrecht, Utrecht, Netherlands.
  • Finfer S; Critical Care Division, The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
  • Hotchkiss RS; Department of Anesthesiology and Critical Care Medicine, Washington University School of Medicine in St Louis, St Louis, MO, USA.
  • Marshall J; Interdepartmental Division of Critical Care, University of Toronto, Toronto, ON, Canada.
  • Openshaw PJM; National Heart and Lung Institute, Imperial College London, London, UK.
  • Seymour CW; Department of Critical Care Medicine, The Clinical Research, Investigation, and Systems Modeling of Acute illness (CRISMA) Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Venet F; Immunology Laboratory, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.
  • Vincent JL; Department of Intensive Care, Hôpital Erasme, Brussels, Belgium.
  • Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay University, Paris, France.
  • Maitland-van der Zee AH; Department of Pulmonary Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
  • McInnes IB; College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
  • van der Poll T; Center for Experimental and Molecular Medicine and Division of Infectious Diseases, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
Lancet Respir Med ; 12(4): 323-336, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38408467
ABSTRACT
Sepsis is a common and deadly condition. Within the current model of sepsis immunobiology, the framing of dysregulated host immune responses into proinflammatory and immunosuppressive responses for the testing of novel treatments has not resulted in successful immunomodulatory therapies. Thus, the recent focus has been to parse observable heterogeneity into subtypes of sepsis to enable personalised immunomodulation. In this Personal View, we highlight that many fundamental immunological concepts such as resistance, disease tolerance, resilience, resolution, and repair are not incorporated into the current sepsis immunobiology model. The focus for addressing heterogeneity in sepsis should be broadened beyond subtyping to encompass the identification of deterministic molecular networks or dominant mechanisms. We explicitly reframe the dysregulated host immune responses in sepsis as altered homoeostasis with pathological disruption of immune-driven resistance, disease tolerance, resilience, and resolution mechanisms. Our proposal highlights opportunities to identify novel treatment targets and could enable successful immunomodulation in the future.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Sepsis / Resistencia a la Enfermedad Límite: Humans Idioma: En Revista: Lancet Respir Med Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Sepsis / Resistencia a la Enfermedad Límite: Humans Idioma: En Revista: Lancet Respir Med Año: 2024 Tipo del documento: Article